It is also approved for adults in the US under the tradename Adbry. Vice president and ... between 12-17 years of age living with atopic dermatitis will now have more treatment options available ...

Proteologix’s lead candidate PX128 targets TSLP – currently drawing a lot of attention among drug developers – and IL-13, a well-validated target in atopic dermatitis, asthma, and other ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Background: Atopic dermatitis (AD) may be exacerbated by occlusion from items such as occlusive gloves or textiles, especially if the occlusion is removed suddenly, creating a steep humidity gradient.

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Wells Fargo analyst Derek Archila maintained a Buy rating on AnaptysBio (ANAB – Research Report) yesterday and set a price target of ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...